Insider Trading: Tom Brown’s Second Curve Capital Files For $PRS

Tom Brown’s Second Curve Capital filed Form 4 for its insider trading in Primus Guaranty Ltd (PRS). According to SEC disclosures, Second Curve Capital recently made several insider transactions in PRS. The latest purchase happened on November 1st when the firm bought 5,518 PRS shares, and retains 5,285,890 shares in its position. Second Curve Capital reported 6.6 million PRS shares in the second quarter, and approximately 5.27 million shares on September 22nd. So now the firm held about 14.85% activist stake in PRS, down by 20% from its position in Q2. PRS has returned about 10% so far, and is now priced at $6.07.

Thomas Brown

Beside Second Curve Capital, David E. Shaw’s D E Shaw also had a position in PRS. D E Shaw reported 101 thousand shares in the stock by the end of the second quarter.

Second Curve Capital was founded in 2000 by award-winning stock analyst Thomas K. Brown. The firm is an employee owned sponsor hedge fund. It provides its services to pooled investment vehicles. The firm had a portfolio value of $242 million and mainly invests in Financial sector. Second Curve Capital was founded in 2000 and is based in New York City.

Primus Guaranty, Ltd. is a credit services company which specializes in credit derivative products. The company sells credit swaps against investment grade credit obligations of corporate and sovereign issuers. The products are primarily offered to global financial institutions and credit swap dealers It also manages credit swap and cash investment portfolios, as well as provides management, consulting, and information technology services. The company was incorporated in 1998 and is headquartered in Hamilton, Bermuda.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!